Any current/future new fundraising through debt or equity?

No specific mention of any current or planned new fundraising through debt or equity in the transcript. The company is focusing on brownfield expansions, such as the Xanthine capacity increase and Atali greenfield project, funded through internal resources or existing plans. CAPEX guidance indicates planned capital expenditure of around INR 550-600 crores over FY25 and FY26, with no explicit discussion on raising fresh capital through equity or debt. The management appears focused on stabilizing and ramping up capacity before considering additional CAPEX or fundraising. No direct questions or

Any current/future capex/capital investment/strategic investment?

Brownfield expansion at current Xanthine site to increase capacity from 5,000 to 9,000 tonnes; project completion expected by Q3 next fiscal year with full operationalization over subsequent 2-3 quarters. Expansion includes filing for USFDA DMF and EUGMP CEP regulatory approvals within current fiscal year, targeting pharmaceutical segment. Atali greenfield project for CDMO/CMO and intermediate manufacturing progressing well; commissioning expected by Q4 FY25; phase one will have 60 reactors (+450 KL capacity) with scope for annual incremental expansions. Additional brownfield expansions and de

Future growth expectations in sales/revenue/volumes?

Xanthine segment capacity expanding from 5000 to 9000 MT, expected full operationalization by FY27 with phased ramp-up starting H2 FY26. Future focus shifting toward pharmaceutical Xanthine in regulated markets, targeting 20-25% capacity allocation to pharma segment to stabilize margins. CDMO/CMO business growth guidance revised lower from 25% to around 20% due to some project delays, but strong growth expected next year and beyond. API segment volumes expected to grow due to capacity debottlenecking and filling Atali intermediate facility in FY26. FY26 growth driven mainly by product mix, sta

Future growth expectations in earnings/operating earnings/profits/EPS?

The company expects EBITDA growth of 10% to 12% in FY25 and a long-term annual growth target of about 15% over the next few years. FY27 is anticipated to be the key year for significant capacity expansions (Xanthine and Atali site) to come online, driving volume growth and margin improvements. CDMO/CMO segment growth might be slightly pushed to FY26 from FY25 due to project timing but is expected to show strong growth going forward. The Xanthine segment is moving from spot to regulated markets, stabilizing margins despite pricing pressures. Continuous cost optimization efforts (e.g., solar ene

Current/ Expected Orderbook/ Pending Orders?

The company is currently working with 19 customers on 55 CDMO/CMO projects. Out of these, 28 projects are in the commercial stage and 27 are in developmental stages. CDMO/CMO orders are multi-stage with long lead times; some high-value orders' deliveries are scheduled later this year, possibly extending revenue realization beyond the current financial year. The company sees increased engagement in CDMO/CMO with more customer visits and RFPs, indicating a strong order pipeline. For API and intermediate segments, capacity expansions and new product commercialization indicate ongoing order growth

IN US

Sale is live|00:00:00left today

Aarti Pharmalabs LtdQ3 FY24Pharmaceuticals & Biotechnology

Aarti Pharmalabs Ltd Q3 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹691P/E: 29.9Market Cap: ₹6.5K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

N/A

Order

Yes

Capex

Yes

2 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 3

→Xanthine segment capacity expanding from 5000 to 9000 MT, expected full operationalization by FY27 with phased ramp-up starting H2 FY26.
→Future focus shifting toward pharmaceutical Xanthine in regulated markets, targeting 20-25% capacity allocation to pharma segment to stabilize margins.
→CDMO/CMO business growth guidance revised lower from 25% to around 20% due to some project delays, but strong growth expected next year and beyond.
→API segment volumes expected to grow due to capacity debottlenecking and filling Atali intermediate facility in FY26.
→FY26 growth driven mainly by product mix, stable volumes, and CDMO/CMO; FY27 anticipated to deliver bulk of 15% CAGR target with new capacities.
→Long-term revenue potential from CDMO projects ranges $25-$50 million per molecule if commercialized successfully.
→Overall, cautious growth guidance aiming to achieve at least 15% EBITDA CAGR over next 3 years.

Margin guidance

Category 3

→The company expects EBITDA growth of 10% to 12% in FY25 and a long-term annual growth target of about 15% over the next few years.
→FY27 is anticipated to be the key year for significant capacity expansions (Xanthine and Atali site) to come online, driving volume growth and margin improvements.
→CDMO/CMO segment growth might be slightly pushed to FY26 from FY25 due to project timing but is expected to show strong growth going forward.
→The Xanthine segment is moving from spot to regulated markets, stabilizing margins despite pricing pressures.
→Continuous cost optimization efforts (e.g., solar energy, bio gas) are expected to support margin improvement.
→Management remains cautious with guidance to avoid over-commitment but confident of surpassing the stated targets in the medium to long term.

3 more insights locked — sign up free to unlock

Fundraise plans

→No specific mention of any current or planned new fundraising through debt or equity in the transcript.
→The company is focusing on brownfield expansions, such as the Xanthine capacity increase and Atali greenfield project, funded through internal resources or existing plans.
→CAPEX guidance indicates planned capital expenditure of around INR 550-600 crores over FY25 and FY26, with no explicit discussion on raising fresh capital through equity or debt.
→The management appears focused on stabilizing and ramping up capacity before considering additional CAPEX or fundraising.
→No direct questions or answers related to new equity or debt issuance were addressed in the sessions on pages 6-16.

Order book

Yes

→The company is currently working with 19 customers on 55 CDMO/CMO projects.
→Out of these, 28 projects are in the commercial stage and 27 are in developmental stages.
→CDMO/CMO orders are multi-stage with long lead times; some high-value orders' deliveries are scheduled later this year, possibly extending revenue realization beyond the current financial year.
→The company sees increased engagement in CDMO/CMO with more customer visits and RFPs, indicating a strong order pipeline.
→For API and intermediate segments, capacity expansions and new product commercialization indicate ongoing order growth.
→The Xanthine segment maintains strong long-term contracts despite spot market pressure; capacity ramp-up expected to boost orderbook.
→Overall, the outlook is positive with strong medium to long-term order pipeline especially in CDMO/CMO and regulated API markets.

Capex plans

Yes

→Brownfield expansion at current Xanthine site to increase capacity from 5,000 to 9,000 tonnes; project completion expected by Q3 next fiscal year with full operationalization over subsequent 2-3 quarters.
→Expansion includes filing for USFDA DMF and EUGMP CEP regulatory approvals within current fiscal year, targeting pharmaceutical segment.
→Atali greenfield project for CDMO/CMO and intermediate manufacturing progressing well; commissioning expected by Q4 FY25; phase one will have 60 reactors (+450 KL capacity) with scope for annual incremental expansions.
→Additional brownfield expansions and debottlenecking planned at Tarapur API site to meet growing demand.
→Total planned CAPEX of ₹550-600 crores over current and next fiscal years:
→ - ₹170 crores invested in H1 FY25
→ - ₹250 crores planned in H2 FY25
→ - ₹150 crores planned in H1 FY26
→No immediate new CAPEX planned for Xanthine beyond current expansion; strategy to stabilize capacity before additional investments.

How does Aarti Pharmalabs Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

1Aarti Pharmalabs Ltd

Rev 3Mar 3

See full Pharmaceuticals & Biotechnology sector rankings

Want more stocks like Aarti Pharmalabs Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio